Avenue Therapeutics, Inc. (ATXI) Stock Forecast
ATXI analyst forecast
as of October 21, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $8.00 average of analyst targets
- Upside to target
- +1,879.2% from the latest close
- Next earnings
- —
- 52-week range
- $0.15 – $0.93
ATXI analyst ratings
1 analystsNumber of analysts at each rating.
ATXI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ATXI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ATXI beat in 4 of 11.
What analysts expect from ATXI
1 analysts cover Avenue Therapeutics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.00, 1,879.2% above the latest close of $0.40. Avenue Therapeutics beat the EPS estimate in 4 of the last 11 quarters.
Related: ATXI income statement, ATXI key metrics, ATXI chart. See the ATXI stock overview for the latest quote and news.
ATXI forecast FAQ
What is Avenue Therapeutics's price target?
The average analyst price target for Avenue Therapeutics is $8.00, 1,879.2% above the latest close of $0.40.
Is Avenue Therapeutics a buy, hold or sell?
Of 1 analysts covering Avenue Therapeutics, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
Does Avenue Therapeutics usually beat earnings estimates?
Avenue Therapeutics reported EPS at or above the analyst estimate in 4 of the last 11 quarters.